Running for the sixth year in a row, EIT Health Catapult boosts the development of European health start-ups by exposing them to leading experts and international investors. Winners are set up to continue on their path and achieve impressive growth. Prizes of €40,000 (for first place), €20,000 (for second place) and €10,000 (for third place) are awarded to three winners in each of the categories: biotech, medtech and digital health, as well as in-kind support from sponsors including Nasdaq, Amazon Web Services, AstraZeneca, Merck, Lusiadas, McDermott Will & Emery and eg technology.
This year 42 mature start-ups have entered the semifinals on the 3rd-5th of December to compete for the chance to get a spot at the finals in May 2022. The start-ups have been trained by top-level experts and investors, giving them access to fully prepared investment cases. The start-ups have been pitching in three different categories on 3 different days during the online event.
Dr. Kurt Höller, Director of Business Creation at EIT Health said about the event: “After the EIT Health Catapult success stories from the past two years, we are thrilled to announce 21 promising start-ups that will compete in our finals live on stage. We look forward to seeing what the winners go on to achieve with our support.”
We are happy to announce that 4 of our supported start-ups have been selected for the finals!
Here are the chosen start-ups:
Limula (Switzerland) saves lives by enabling widespread access to the latest generation of personalized cancer treatments. Their platform technology supports the scale-out of production, bringing automated manufacturing of cell therapies directly to patients at the point of care. Their USP lies in the unique design of their bench-top device and associated single-use consumables. By automating all steps of cell therapy production in a single device, the technology removes the need for large facilities and manual interventions. By bringing manufacturing closer to the patient, Limula´s solution saves time, cuts costs, simplifies logistics and ultimately increases accessibility to these revolutionary cancer treatments.
Thinksono (Germany) is a world-leading ultrasound AI company. It has created the world’s first software for automatic detection of deep vein thrombosis (DVT). DVT is the number one cause of preventable hospital death. With ThinkSono’s technology, a nurse or a junior doctor can detect DVT in as little as 5 minutes. This can be done at the point of care and at the fraction of the current diagnostic costs. Thus saving time, money and lives.
Digital health category
Ebenbuild (Germany): Since the lung is a complete black box to even expert physicians, mechanical ventilation (MV) is a rare skill founded on experience and educated guesses. Good MV must become easier and reproducible anywhere. Ebenbuild solves this problem. Their first of a kind simulation/AI software hybrid generates unprecedented data of the patient’s lung, enabling doctors to provide better-personalized therapy for Acute Respiratory Distress Syndrome (ARDS) and improving the patients’ odds of survival and recovery.
Mentalis (Germany) provides evidence-based digital aftercare that combines algorithm-driven app therapy and instant psychological tele-support. Mentalis picks up seamlessly from hospital treatment, as it is integrated into the hospital discharge process. So, mentalis is maximally patient-oriented, resulting in high adherence and completer rates. The conducted and ongoing clinical trials together with numerous partners show: mentalis programs are effective and patients improve significantly.
Besides making it to the finals, some of these start-ups received a sponsor prize as well. Thinksono won the Lusiadas for the Future prize, and Mentalis won the Amazon Web Services Prizes, which means a $25k worth of promotional credits and 3o minutes business bank of sessions.
Congratulations to the winning teams! We are rooting for you for the finals at the EIT Health Summit in Stockholm!